<DOC>
	<DOCNO>NCT00711594</DOCNO>
	<brief_summary>The objective Phase I step estimate MTD dose level 50 mg/day ( i.e. , overseas recommend Phase II dose ) patient advance NSCLC determine recommend dose Phase II step . The objective Phase II step estimate efficacy BIBW 2992 monotherapy patient first generation EGFR-TKI-resistant advance NSCLC recommend dose determined Phase I step .</brief_summary>
	<brief_title>LUX-Lung 4 : BIBW 2992 ( Afatinib ) Phase I Trial Advanced Non Small Cell Lung Cancer Patients &amp; Phase II Trial Non Small Cell Lung Cancer Patients Failing Erlotinib Gefitinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : Phase II step ; 1 . Patients pathologic confirmation NSCLC tissue diagnosis cytologic diagnosis , whose NSCLCs locally advance metastatic Stage IIIB / IV adenocarcinoma , inoperable incurable radiotherapy . 2 . Patients receive following pretreatments treatment relapse metastatic NSCLC . Patients receive least one two line chemotherapy . ( `` Chemotherapy '' mean first line ( doublet chemotherapy include platinum ) and/or second line ( single chemotherapy except platinum ) cytotoxic chemotherapy accord standard chemotherapy , erlotinib ( Tarceva® ) gefitinib ( Iressa® ) exclude . One chemotherapy regimens must platinumbased . In addition , one prior cytotoxic chemotherapy treatment regimen allow adjuvant chemotherapy contain platinum . More two prior cytotoxic chemotherapy treatment regimens allow . ) After chemotherapy , patient get clinical benefit ( i.e . complete response , partial response stable disease ) progress follow least 12 week treatment erlotinib ( Tarceva® ) gefitinib ( Iressa® ) recent treatment . ( `` Clinical benefit '' `` progression '' confirm compute tomography ( CT ) magnetic resonance imaging ( MRI ) . In addition , `` least 12 week treatment '' 9 week actual `` treatment period except treatment pause due adverse event reason . ) As long treatment erlotinib gefitinib monotherapy , patient receive multiple regimen either treatment , one regimens least 12 week 3 . Male female patient age &gt; =20 year enrolment . 4 . Life expectancy least three ( 3 ) month start administration investigational drug . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance Score 0 1 . 6 . Patients least one tumor lesion accurately measure CT MRI least one dimension long diameter record less double slice thickness &gt; =10 mm . 7 . Written inform consent consistent ICHGCP guideline . Exclusion criterion : Phase II step ; 1 . Use erlotinib ( Tarceva® ) gefitinib ( Iressa® ) within two week start study medication . 2 . Patients receive definitive thoracic radiotherapy curative intent . Patients receive radiotherapy investigational drug ( nononcological ) within four week enrolment . 3 . Significant gastrointestinal disorder diarrhea major symptom e.g. , Crohn 's disease , malabsorption , CTCAE Grade &gt; 2 diarrhea etiology enrolment . 4 . Patients distinct / suspect pulmonary fibrosis interstitial lung disease chest radiographic finding , patient previous history . 5 . Brain tumor , / brain metastasis , symptomatic require treatment enrolment . 6 . Other malignancy diagnose within past five year ( carcinoma situ gastric cancer , colon cancer cervical cancer , non melanomatous skin cancer ) . 7 . History uncontrolled cardiac disease angina myocardial infarction within past 6 month enrolment , congestive heart failure include New York Heart Association ( NYHA ) functional classification 3 , arrhythmia require treatment . 8 . Coelomic fluid retention ( pleural effusion , ascites pericardial effusion ) require treatment . 9 . Uncontrolled concomitant disease ( e.g . diabetes mellitus , hypertension etc ) . 10 . History serious drug hypersensitivity . 11 . Patients sufficient baseline organ function whose laboratory data meet follow criterion enrolment.11 Haemoglobin count &gt; =9.0 g/dL Absolute neutrophil count ( ANC ) &gt; =1500 / mm3 Platelet count &gt; =100 000 / mm3 Serum creatinine &lt; =1.5 mg/dL Total bilirubin &lt; =1.5 mg/dL Aspartate aminotransferase ( AST ) / alanine aminotransferase ( ALT ) &lt; =2.5x upper limit normal range ( relate liver metastasis &lt; =2.5x upper limit normal also ) PaO2 &gt; =60torr SpO2 &gt; =92 % LVEF measure echocardiography multigated blood pool image heart ( MUGA scan ) &gt; =50 % QTc interval &lt; 0.47 second 12 . Patients disagree use medically acceptable method contraception administration investigational drug least 6 month end administration . 13 . Pregnant breastfeed woman , woman suspect pregnant . 14 . Known positive HBs antigen , HCV antibody , HIV antibody test . 15 . Known suspected active drug alcohol abuse . 16 . Other patient judge ineligible enrolment study investigator ( subinvestigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>